Association of extent of resection on recurrence-free survival and functional outcome in vestibular schwannoma of the elderly.
acoustic neuroma
elderly
geriatric
neuro-oncology
skull base
vestibular schwannoma
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
30
01
2023
accepted:
02
05
2023
medline:
21
6
2023
pubmed:
21
6
2023
entrez:
21
6
2023
Statut:
epublish
Résumé
Despite the ongoing debate on the risk-benefit ratio of vestibular schwannoma (VS) treatment options, watchful observation and radiation are usually favored in the elderly (>65 years). If surgery is inevitable, a multimodal approach after deliberate subtotal resection has been described as a valid option. The relationship between the extent of resection (EOR) of surgical and functional outcomes and recurrence-free survival (RFS) remains unclear. This present study aims to evaluate the functional outcome and RFS of the elderly in relation to the EOR. This matched cohort study analyzed all consecutive elderly VS patients treated at a tertiary referral center since 2005. A separate cohort (<65 years) served as a matched control group (young). Clinical status was assessed by the Charlson Comorbidity Index (CCI), the Karnofsky Performance (KPS), and the Gardner and Robertson (GR) and House & Brackmann (H&B) scales. RFS was evaluated by Kaplan-Meier analysis using contrast-enhanced magnetic resonance imaging to identify tumor recurrence. Among 2,191 patients, 296 (14%) patients were classified as elderly, of whom 133 (41%) were treated surgically. The elderly were characterized by a higher preoperative morbidity and worse gait uncertainty. Postoperative mortality (0.8% and 1%), morbidity (13% and 14%), and the functional outcome (G&R, H&B, and KPS) did not differ between the elderly and the young. There was a significant benefit in regard to the preoperative imbalance. Gross total resection (GTR) was accomplished in 74% of all cases. Lower grades of the EOR (subtotal and decompressive surgery) raised the incidence of recurrence significantly. Mean time to recurrence in the Surgical VS treatment aiming for complete tumor resection is feasible and safe, even in advanced age. A higher EOR is not associated with cranial nerve deterioration in the elderly compared to the young. In contrast, the EOR determines RFS and the incidence of recurrence/progression in both study cohorts. If surgery is indicated in the elderly, GTR can be intended safely, and if only subtotal resection is achieved, further adjuvant therapy, e.g., radiotherapy, should be discussed in the elderly, as the incidence of recurrence is not significantly lower compared to the young.
Sections du résumé
Background
UNASSIGNED
Despite the ongoing debate on the risk-benefit ratio of vestibular schwannoma (VS) treatment options, watchful observation and radiation are usually favored in the elderly (>65 years). If surgery is inevitable, a multimodal approach after deliberate subtotal resection has been described as a valid option. The relationship between the extent of resection (EOR) of surgical and functional outcomes and recurrence-free survival (RFS) remains unclear. This present study aims to evaluate the functional outcome and RFS of the elderly in relation to the EOR.
Methods
UNASSIGNED
This matched cohort study analyzed all consecutive elderly VS patients treated at a tertiary referral center since 2005. A separate cohort (<65 years) served as a matched control group (young). Clinical status was assessed by the Charlson Comorbidity Index (CCI), the Karnofsky Performance (KPS), and the Gardner and Robertson (GR) and House & Brackmann (H&B) scales. RFS was evaluated by Kaplan-Meier analysis using contrast-enhanced magnetic resonance imaging to identify tumor recurrence.
Results
UNASSIGNED
Among 2,191 patients, 296 (14%) patients were classified as elderly, of whom 133 (41%) were treated surgically. The elderly were characterized by a higher preoperative morbidity and worse gait uncertainty. Postoperative mortality (0.8% and 1%), morbidity (13% and 14%), and the functional outcome (G&R, H&B, and KPS) did not differ between the elderly and the young. There was a significant benefit in regard to the preoperative imbalance. Gross total resection (GTR) was accomplished in 74% of all cases. Lower grades of the EOR (subtotal and decompressive surgery) raised the incidence of recurrence significantly. Mean time to recurrence in the
Conclusions
UNASSIGNED
Surgical VS treatment aiming for complete tumor resection is feasible and safe, even in advanced age. A higher EOR is not associated with cranial nerve deterioration in the elderly compared to the young. In contrast, the EOR determines RFS and the incidence of recurrence/progression in both study cohorts. If surgery is indicated in the elderly, GTR can be intended safely, and if only subtotal resection is achieved, further adjuvant therapy, e.g., radiotherapy, should be discussed in the elderly, as the incidence of recurrence is not significantly lower compared to the young.
Identifiants
pubmed: 37342182
doi: 10.3389/fonc.2023.1153698
pmc: PMC10277928
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1153698Informations de copyright
Copyright © 2023 Wang, Machetanz, Ebner, Naros and Tatagiba.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Neurol Med Chir (Tokyo). 2006 Apr;46(4):176-80; discussion 180-1
pubmed: 16636507
J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39
pubmed: 13406590
Lancet. 2016 Oct 8;388(10053):1545-1602
pubmed: 27733282
World Neurosurg. 2017 May;101:457-465
pubmed: 28192265
N Engl J Med. 1998 Nov 12;339(20):1426-33
pubmed: 9811917
J Neurosurg. 2016 Dec;125(Suppl 1):64-72
pubmed: 27903183
J Neurosurg. 2014 Jan;120(1):207-17
pubmed: 23870020
Neuro Oncol. 2011 Nov;13(11):1252-9
pubmed: 21856684
Otol Neurotol. 2003 Jan;24(1):118-22
pubmed: 12544040
Neurosurgery. 2011 Jan;68(1):68-77
pubmed: 21099722
Otol Neurotol. 2021 Feb 1;42(2):e199-e208
pubmed: 33177408
Neurosurgery. 1991 May;28(5):646-50; discussion 650-1
pubmed: 1876241
Ann Surg. 2009 Aug;250(2):187-96
pubmed: 19638912
J Neurosurg. 1998 Mar;88(3):506-12
pubmed: 9488305
J Neurosurg. 2017 May 19;:1-7
pubmed: 28524795
J Peripher Nerv Syst. 2000 Dec;5(4):191-208
pubmed: 11151980
Lancet. 2002 Jul 27;360(9329):309-10
pubmed: 12147377
N Engl J Med. 2021 Apr 8;384(14):1335-1348
pubmed: 33826821
J Neurol Surg B Skull Base. 2019 Apr;80(2):156-164
pubmed: 30931223
Front Neurol. 2019 Jan 29;10:43
pubmed: 30761075
J Neurol Surg B Skull Base. 2012 Apr;73(2):117-20
pubmed: 23542125
Neuro Oncol. 2020 Jan 11;22(1):31-45
pubmed: 31504802
Acta Neurochir (Wien). 2020 Nov;162(11):2629-2636
pubmed: 32712719
Neuro Oncol. 2006 Jan;8(1):27-37
pubmed: 16443945
Neurosurgery. 1992 Oct;31(4):615-9; discussion 619-20
pubmed: 1407445
J Clin Oncol. 1984 Mar;2(3):187-93
pubmed: 6699671
Ann Otol Rhinol Laryngol. 1988 Jan-Feb;97(1):55-66
pubmed: 3277525
Neuro Oncol. 2022 Oct 5;24(Suppl 5):v1-v95
pubmed: 36196752
Neurosurg Focus. 2012 Sep;33(3):E14
pubmed: 22937848
BMJ Open. 2013 Feb 22;3(2):
pubmed: 23435793
JAMA Oncol. 2016 Nov 01;2(11):1460-1469
pubmed: 27310651
J Clin Epidemiol. 1994 Nov;47(11):1245-51
pubmed: 7722560
Neurosurg Focus. 2012 Sep;33(3):E8
pubmed: 22937859